PEAQX (10-40 mg/kg) dose-dependently increased cortical caspase-3 activity following sub-chronic administration.
PEAQX (10 and 20 mg/kg) shows enhanced locomotor activity in response to PCP challenge (4 mg/kg on PN28-35) compared to saline pretreatment (F3, 73=4.99).
PEAQX (10 mg/kg, ip) antagonizes the effects of PRE084 on CaMKIV-TORC1-CREB and BDNF, even for learning and memory impairment.
| Animal Model: |
Timed, day 14 pregnant female Sprague-Dawley rats. |
| Dosage: |
10, 20 or 40 mg/kg. |
| Administration: |
S.C. |
| Result: |
Showed a sensitized locomotor response to PCP challenge on PN28-35. |
| Animal Model: |
Timed, day 14 pregnant female Sprague-Dawley rats. |
| Dosage: |
4 mg/kg. |
| Administration: |
I.P. |
| Result: |
Did not significantly increase locomotor activity in rats treated sub-chronically with PEAQX on PN7, 9 and 11. |
| Animal Model: |
11-week old C57BL/6 mice. |
| Dosage: |
10 mg/kg. |
| Administration: |
IP. |
| Result: |
Reversed the effect of PRE084 (F3,78 = 10.446, p<0.01). |